aztreonam / Generic mfg. - LARVOL DELTA

On the optimal treatment of Metallo-Beta-Lactamase-producing Enterobacterales infections using aztreonam and avibactam. (PubMed, Clin Infect Dis) - No abstract available

Journal • Infectious Disease

Revisiting REVISIT: The Case for Ceftazidime/avibactam Plus Aztreonam. (PubMed, Clin Infect Dis) - No abstract available

Journal

CEFTAZIDIME-AVIBACTAM PLUS AZTREONAM IN MANAGING MULTIDRUG-RESISTANT GRAM-NEGATIVE INFECTIONS IN PAEDIATRICS: A SINGLE-CENTRE CASE SERIES. (ESPID 2025) - "Background Aztreonam-avibactam targets multidrug-resistant (MDR) Gram-negative pathogens, including those producing metallo-β-lactamases (MBL). Combination of aztreonam-avibactam has recently been licensed to use in adults and may soon be available in children. Larger trials are needed to establish its efficacy and place in paediatric guidelines."

Clinical • Gram negative • Infectious Disease

A highly virulent BA-producing Burkholderia gladioli strain linked to a fatal foodborne outbreak in China, 2020. (PubMed, Infect Genet Evol) - "This outbreak highlights the dual threat of hypervirulent BA production and intrinsic multidrug resistance in B. gladioli. The absence of CLSI breakpoints for this pathogen complicates clinical susceptibility interpretations, yet YD01's resistance profile suggests limited therapeutic options in empirical treatment. Enhanced surveillance, species-specific antimicrobial guidelines, and rapid diagnostics targeting both bon and resistance genes are urgently needed to mitigate future risks."

Journal • Gastroenterology • Gastrointestinal Disorder

l-2,3-Diaminopropionate Binding Mode of the SulM Adenylation Domain Limits Engineering Monobactam Analogue Biosynthesis with Larger Substrates. (PubMed, JACS Au) - "The recent FDA approval of Emblaveo to treat serious bacterial infections combines an established synthetic monobactam aztreonam and avibactam, which additionally blocks serine β-lactamases, to create a broadly effective antibacterial therapeutic. Comparisons with the structures of other diamino acid-activating adenylation domains identify alternate binding modes that may be more suitable for the production of sulfazecin analogues. The impact of these structures on the further engineering of the SulA3 domain and its relation to monobactam synthesis in the recently structurally characterized SulTE are discussed."

Journal • Infectious Disease

Pharmacodynamics of aztreonam/ceftazidime/avibactam and polymyxin B versus New Delhi MBL-producing Acinetobacter baumannii. (PubMed, JAC Antimicrob Resist) - "Monte Carlo simulations of human pharmacokinetics of aztreonam showed that package insert dosing resulted in a average free steady-state concentration above the target aztreonam IC50 values for AR-0033 ≥96% of time when in combination with ceftazidime/avibactam and PMB. This study supports the potential utility of low-dose PMB therapy in combination with β-lactams to combat NDM-producing CRAB."

Journal • PK/PD data

Aztreonam Acts as a Synergist for Ceftazidime/Avibactam Against Carbapenem-Resistant Enterobacteriaceae (CRE) of Various Carbapenemase Phenotypes in Southwestern China. (PubMed, Infect Drug Resist) - "All 87 CRE strains showed high resistance to most antibiotics, especially cefazolin, ceftriaxone, piperacillin/tazobactam, ertapenem, and meropenem, with a rate of 100.00%. Notably, The combination of CZA and ATM showed synergy in 95.40% (83/87) of the CRE strains overall, with specific rates of 100.00% (4/4) in strains lacking detectable carbapenemase genes, 94.29% (33/35) in those with blaNDM, and 100.00% (3/3) in those with blaNDM plus blaKPC-2 or blaKPC-2 plus blaIMP-4. In conclusion, ATM significantly enhances CZA's activity against CRE strains in Guangxi, achieving a high synergy rate across diverse isolates, regardless of the carbapenemase genes present."

Journal • Infectious Disease • Pneumonia • Pulmonary Disease • Respiratory Diseases

Integral-2: P3 Study to Assess Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available Therapy for Adults With Infection Due to Carbapenem Resistant Enterobacterales (clinicaltrials.gov) - P3 | N=150 | Recruiting | Sponsor: Meiji Seika Pharma Co., Ltd. | Trial completion date: Feb 2025 ➔ Sep 2025 | Trial primary completion date: Feb 2025 ➔ Sep 2025

Trial completion date • Trial primary completion date • Infectious Disease • Nephrology • Pneumonia • Respiratory Diseases

Detection of ESBL-producing Klebsiella oxytoca complex with VITEK 2 system and screening cutoffs for implementing confirmatory tests. (PubMed, J Clin Microbiol) - "We also analyzed KoC-specific screening cutoffs for ceftriaxone (CRO), cefpodoxime (CPD), ceftazidime (CAZ), cefotaxime (CTX), and aztreonam (ATM) to negate unnecessary ESBL-CTs. In contrast, VITEK 2 alone followed by the ESBL screen and phenotypic confirmatory tests provides accurate differentiation. Since this latter approach increases the diagnostic workload, we also proposed new screening cutoffs for key cephalosporins that may reduce the current high number of unnecessary confirmatory tests."

Journal

A Rare Case of Fatal Necrotizing Fasciitis and Bacteremia From Myroides Odoratimimus (ATS 2025) - "3 days prior to presentation, the patient reported that he slipped while getting out of the shower, hit his head and scraped his arm and leg. He was started on vancomycin and piperacillin-tazobactam, and fluid resuscitated with ∼35cc/kg of crystalloid...Ultimately the strain isolated in our patient was resistant to piperacillin-tazobactam, as well as cephalosporins, aztreonam, ciprofloxacin and aminoglycosides. We resorted to using a combination of 3 antibiotics - TMP-SMX, meropenem and levofloxacin - however, the amount of antibiotics required for successful treatment is unclear and not noted in literature. Despite finally being on appropriate antibiotics and surgical intervention, the patient succumbed to his illness.-"

Clinical • Amyloidosis • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Coronary Artery Disease • Dermatology • Diabetes • Diabetic Nephropathy • Heart Failure • Hematological Disorders • Hematological Malignancies • Infectious Disease • Lymphoma • Lymphoplasmacytic Lymphoma • Metabolic Disorders • Pain • Renal Disease • Type 2 Diabetes Mellitus • Waldenstrom Macroglobulinemia

A Vein of Trouble: Lemierre's Syndrome Presenting With Septic Thrombophlebitis (ATS 2025) - "On arrival, the patient was on norepinephrine, vancomycin, metronidazole, and aztreonam. With timely identification and appropriate antimicrobial therapy, mortality falls dramatically to 2-5%. Although rare, Lemierre's Syndrome should be considered in cases of undifferentiated septic shock."

Cardiovascular • Hematological Disorders • Infectious Disease • Metabolic Disorders • Otorhinolaryngology • Pulmonary Embolism • Septic Shock • Thrombosis

In vitro Evaluation of the Antibacterial Activity of the Combination of Avibactam and β-Lactams Against Highly Virulent Carbapenem-Resistant Klebsiella pneumoniae. (PubMed, Infect Drug Resist) - "The combination of carbapenems, cephalosporins, and aztreonam with avibactam significantly lowered MIC values compared to single drugs (P<0.01)...CRKP harbouring virulence genes poses significant risks. Combining carbapenems, cephalosporins, and avibactam enhances antibacterial activity against CRKP."

Journal • Preclinical • Infectious Disease • Pneumonia

Extended-Spectrum-Beta-Lactamase (ESBL)-Producing Escherichia coli in Laying Hens: Slaughterhouse Prevalence and Antibiotic Resistance Patterns. (PubMed, Antibiotics (Basel)) - "The presence of these genes was strongly associated with resistance to ampicillin, amoxicillin-clavulanic acid, aztreonam, cefepime, cefpodoxime, cefuroxime, and cephalothin, highlighting the critical role of blaCTX-M in driving the multidrug resistance patterns observed in this study. The highest resistance rate (80%) was observed in "personnel" and "carcass samples after evisceration", while all isolates remained sensitive to carbapenems (imipenem and meropenem). Our findings highlight the importance of the laying hen slaughter line as a potential source of contamination with ESBL-producing E. coli, which poses significant implications for food safety and public health. These findings underscore the need for improved control measures to mitigate ESBL E. coli transmission in poultry processing and highlight the importance of optimizing antibiotic use strategies in laying hen farming."

Journal

Extended-Spectrum β-Lactamase-Producing Klebsiella pneumoniae in Dogs from Cape Verde and São Tomé and Príncipe: Implications for Public Health. (PubMed, Antibiotics (Basel)) - "Antimicrobial susceptibility testing showed 100% resistance to aztreonam, cefotaxime, cefpodoxime, and ceftaroline, and high resistance to cefepime (93.8%), ciprofloxacin (93.8%), and trimethoprim/sulfamethoxazole (90.6%). All isolates were considered multidrug-resistant but remained susceptible to cefoxitin, imipenem, and meropenem...DNA fingerprinting revealed seven clusters, suggesting genetic diversity and strain dissemination across locations. These findings highlight the role of dogs as vectors for antimicrobial resistance dissemination, underscoring the need for continuous surveillance in both veterinary and human medicine."

Journal • Infectious Disease • Pneumonia

Targeted 'knock out' therapy with a combination antimicrobial regimen restores treatment options in the management of extensively drug-resistant carbapenemase-producing organisms. (PubMed, J Med Microbiol) - "Cefiderocol (FDC) and the combination of ceftazidime-avibactam and aztreonam (CZA+ATM) are emerging therapeutic options to combat carbapenemase-producing organisms (CPOs) that exhibit resistance due to multiple β-lactamases.Hypothesis/Gap Statement...To evaluate the in vitro efficacy of FDC and CZA+ATM against CPOs and to compare colistin (CST) MICs obtained locally with those from the reference laboratory.Methodology...The VITEK2 may provide presumptive categorical information for CST susceptibility, but MICs must be confirmed by broth microdilution as VMEs can lead to treatment failures. Moreover, our study confirms potent in vitro activity of CZA+ATM against CPOs expressing multiple β-lactamases."

Journal • Infectious Disease

Gut colonization guided versus routine empiric antimicrobial therapy to manage infections in patients with cirrhosis: a pragmatic randomized trial (EASL 2025) - "Of 43 carbapenemase-positive patients, 40 in the intervention group received ceftazidime-avibactam plus aztreonam or polymyxin-based therapy. This is the first randomized trial to show that Xpert Carba-R and rectal colonization- guided antimicrobials improve survival, infection resolution, and organ function in cirrhosis patients with infections. These findings support integrating gut colonization assessments into the routine care of cirrhosis patients."

Clinical • Fibrosis • Hepatology • Immunology • Infectious Disease • Oncology • Pneumonia • Respiratory Diseases

Prevalence of New Delhi Metallo-β-lactamase (blaNDM) gene in a selected population of drug-resistant clinical isolates. (PubMed, Mol Biol Rep) - "The high prevalence of blaNDM in our study has of great concern for clinical practice and public health. Clinicians are left with few therapeutic options. However, ceftazidime/avibactam with aztreonam may show therapeutic success. Continuous surveillance is crucial to monitorgenetic variations of continuously evolving blaNDM gene, which is essential for effective clinical management."

Journal • Infectious Disease

Evaluation of Biofilm Production and Antibiotic Resistance/Susceptibility Profiles of Pseudomonas spp. Isolated from Milk and Dairy Products. (PubMed, Foods) - "All strains were susceptible to amikacin and tobramycin; however, 73% of the strains were resistant to aztreonam, 28% to imipenem and doripenem, 19% to ceftazidime, 13% to meropenem, and 7% to cefepime. These findings highlight Pseudomonas spp. as persistent contaminants and antibiotic resistance reservoirs in dairy environments and products, posing public health risks and economic implications for the dairy industry."

Journal

Antibiotic use and financial impact of a comprehensive beta-lactam allergy management program. (PubMed, Antimicrob Steward Healthc Epidemiol) - "NBL DOT-A was 944.8/1000DT (8.8 DOT-A per intervention) accounting for an estimated cost savings of $206,500 ($344.10 per intervention), driven primarily by aztreonam avoidance. This study highlights significant avoidance of NBL DOT in one of the largest identified cohort of inpatients undergoing PST. Associated cost avoidance contributes to the sustainability and longevity of the allergy management program."

Journal • Allergy • Immunology • Infectious Disease

"Rapid identification of carbapenemases and in vitro synergy testing of ceftazidime-avibactam with aztreonam in extensively drug-resistant Gram-negative pathogens: Establishing the realm of promise". (PubMed, Indian J Med Microbiol) - "The CZA-ATM combination demonstrated synergy in 40% of isolates, with 75% of patients receiving this combination achieving microbiological clearance. This simple, rapid synergy testing method can guide effective therapeutic decisions in resource-limited settings."

Journal • Preclinical • Infectious Disease

Serovar distribution, virulence gene and antibiotic susceptibility profiling of Salmonella enterica isolated from seafood in Mumbai, India. (PubMed, Microb Pathog) - "The antibiotic susceptibility testing revealed that the isolates were resistant against third-generation cephalosporins, quinolones, fluoroquinolones and tetracycline antibiotics, but sensitive to ceftazidime, aztreonam, carbapenems, chloramphenicol, and aminoglycosides. The diverse serovars of Salmonella contaminating fresh seafood in this geographical region constitute a notable public health concern."

Journal

Management of Severe Infections: Multidrug-Resistant and Carbapenem-Resistant Gram-Negative Bacteria. (PubMed, Med Clin North Am) - "For Enterobacterales, it highlights the relative advantages of meropenem-vaborbactam and imipenem-relebactam in treating Klebsiella pneumoniae carbapenemase (KPC)-producing strains with resistance to ceftazidime-avibactam, the preference for ceftazidime-avibactam in addressing oxacillin-hydrolyzing carpapenemase (OXA)-48-like -producing organisms, and the combination of ceftazidime-avibactam with aztreonam for metallo-β-lactamase (MBL)-producing Enterobacterales. Regarding A baumannii, sulbactam-durlobactam is identified as the preferred treatment, while ceftolozane-tazobactam, ceftazidime-avibactam, and imipenem-relebactam are viable options for P aeruginosa. Additionally, cefiderocol is presented as an alternative for MBL-producing carbapenem-resistant gram-negative bacteria."

Journal • Review • Infectious Disease • Pneumonia

Study on the invitro synergistic susceptibility and biofilm inhibition mechanism of ceftazidime-avibactam combined with aztreonam against carbapenem-resistant Klebsiella pneumoniae. (PubMed, Front Microbiol) - "The combination of ATM and CZA shows a strong synergistic antibacterial effect against CRKP strains with various enzyme types, with particularly notable synergy in strains carrying the blaKPC-2 resistance gene. Additionally, this combination significantly disrupts the cellular structure of CRKP and inhibits biofilm formation."

Journal • Preclinical • Infectious Disease • Pneumonia • Respiratory Diseases

COLONIZATION BY CARBAPENEM-RESISTANT BACTERIA IS ASSOCIATED WITH CARBAPENEM-RESISTANT BLOODSTREAM INFECTIONS WITH DISMAL OUTCOME IN THE IMMEDIATE POST-TRANSPLANT PHASE (EBMT 2025) - "EAT used in the 13 CR BSI episodes included Piperacillin-Tazobactam plus Amikacin, Ceftazidime-Avibactam, Ceftazdime-Avibactam plus Aztreonam and Meropenem plus Colistin in 6 (46.2%), 3 (23.1%), 1 (7.7%) and 3 cases (23.1%), respectively. Despite the limitations of small sample size, we showed that CR colonization is associated with increased risk of CR-BSI in the acute phase following HCT. This risk appears to decrease in later post-HCT phases and after chemotherapy cycles. CR-BSI occurring early post-HCT are linked to poorer outcomes, underscoring the need for effective infection prevention and eradication strategies."

Post-transplantation • Hematological Disorders • Infectious Disease • Pediatrics • Septic Shock • Transplantation • CRP

COLONIZATION BY CARBAPENEM-RESISTANT BACTERIA IS ASSOCIATED WITH CARBAPENEM-RESISTANT BLOODSTREAM INFECTIONS WITH DISMAL OUTCOME IN THE IMMEDIATE POST-TRANSPLANT PHASE (EBMT 2025) - "EAT used in the 13 CR BSI episodes included Piperacillin-Tazobactam plus Amikacin, Ceftazidime-Avibactam, Ceftazdime-Avibactam plus Aztreonam and Meropenem plus Colistin in 6 (46.2%), 3 (23.1%), 1 (7.7%) and 3 cases (23.1%), respectively. Despite the limitations of small sample size, we showed that CR colonization is associated with increased risk of CR-BSI in the acute phase following HCT. This risk appears to decrease in later post-HCT phases and after chemotherapy cycles. CR-BSI occurring early post-HCT are linked to poorer outcomes, underscoring the need for effective infection prevention and eradication strategies."

Post-transplantation • Hematological Disorders • Infectious Disease • Pediatrics • Septic Shock • Transplantation • CRP